RxDoctor Payments Data

Regina Ledford

Family · Shelby, NCNPI 1821719717

Payments from drug & device makers

$595in general payments, 2019–2025

Across 31 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$144
  • AstraZeneca$105
  • Novo Nordisk$105
  • GSK$61
  • Boehringer Ingelheim$39
  • Boston Scientific$29
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$595100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$595 in reported general payments places this provider in the 60th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$9,949
Medicare patients
85
Services billed
222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin75$93,872
OzempicSemaglutide63$68,050
FarxigaDapagliflozin Propanediol43$49,641
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$43,349
LinzessLinaclotide31$36,953
TrulicityDulaglutide34$33,189
DescovyEmtricitabine/Tenofov Alafenam12$30,650
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$25,330
JanuviaSitagliptin Phosphate18$25,219
MounjaroTirzepatide22$25,217
TradjentaLinagliptin24$19,966
Bydureon BciseExenatide Microspheres13$16,002
EliquisApixaban15$12,101
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$10,868
Breo ElliptaFluticasone/Vilanterol13$10,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$39$113,83899 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Bevespi Aerosphere$105$87,494117 claims
Novo NordiskOzempic$105$68,05063 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$61$64,82365 claims
AbbVieLinzess$144$36,95331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,522 family providers in North Carolina.

Other family in Shelby

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →